Breast Cancer Expert Focuses on Decoding BiomarkersFebruary 2nd 2023
For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.
Use of Neoadjuvant Endocrine Therapy Showcases Testing Capabilities in Breast CancerOctober 6th 2019
In breast cancer, neoadjuvant endocrine therapy shows promise in a variety of areas, including as an excellent testing platform, Ingrid A. Mayer, MD, MSCI, said in a presentation during the 2019 Lynn Sage Breast Cancer Symposium.
Trends in Pathologic Complete Response After Neoadjuvant Chemo in Breast CancerOctober 5th 2019
In contemporary breast cancer clinical practice, the correlation between achieving a pathologic complete response after neoadjuvant chemotherapy and significantly improved outcomes after chemotherapy has been well established. However, in a discussion at the 2019 Lynn Sage Breast Cancer Symposium, William J. Gradishar, MD, cautioned colleagues that there is more to the story when one looks at long-term data in these patients.
Multipronged De-Escalated Chemo Strategy Could Yield Best Results in HER2+ Breast CancerOctober 5th 2019
As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.
Emerging Role of TILs in Breast Cancer Leads to Expanding Pathology PracticesOctober 12th 2018
Just as immunotherapies are transforming clinical practice for oncologists, these new therapies are also changing the practice of pathology and offering new ways for oncologists and pathologists to collaborate and improve patient care.
Ibrutinib-containing Combination Induced High Rate of Bone Marrow MRD Negativity, 100% ORR in IGHV-Mutated CLLJuly 12th 2017
Patients with IGHV-mutated chronic lymphocytic leukemia had high rates of minimal residual disease-negative status in bone marrow following first-line treatment with a combination of ibrutinib (Imbruvica), fludarabine, cyclophosphamide, and obinutuzumab.
Study Further Characterizes Niraparib PFS Benefit in Ovarian CancerJune 9th 2017
Patients with ovarian cancer who had a partial response to previous platinum-based therapy had superior progression-free survival with or without germline BRCA mutations after treatment with niraparib (Zejula), according to a posthoc analysis of data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.